Trial record 3 of 4 for:
acoramidis | Phase 3
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03860935 |
Recruitment Status :
Completed
First Posted : March 4, 2019
Last Update Posted : July 10, 2023
|
Sponsor:
Eidos Therapeutics, a BridgeBio company
Information provided by (Responsible Party):
Eidos Therapeutics, a BridgeBio company
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 11, 2023 |
Actual Study Completion Date : | May 11, 2023 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
May 10, 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):